Scholars@Duke
construction release_alert
Scholars@Duke will be undergoing maintenance on Wed., Feb. 4 from 5-6pm ET. Some site features like search and browse may not work during this time.
cancel
Jon Paul Gockerman

Jon Paul Gockerman

Professor Emeritus of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
Duke Box 3872, Durham, NC 27710
25154 Morris Bldg, Durham, NC 27710

Selected Publications

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.

Journal Article Leuk Res · January 2013 PURPOSE: The decision to re-induce patients with acute myeloid leukemia (AML) based on results of the day 14 bone marrow (BM) biopsy is variable and lacks evidence based data. The aim of our review was to evaluate the accuracy of a day 14 BM biopsy in dete ... Full text Link to item Cite

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.

Journal Article Leukemia · January 2013 Chronic lymphocytic leukemia (CLL) can be immunosuppressive in humans and mice, and CLL cells share multiple phenotypic markers with regulatory B cells that are competent to produce interleukin (IL)-10 (B10 cells). To identify functional links between CLL ... Full text Link to item Cite

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

Journal Article Cancer Chemother Pharmacol · July 2012 PURPOSE: Preclinical data suggest concurrent inhibition of VEGF, mTOR and EGFR pathways may augment antitumor and antiangiogenic effects compared to inhibition of each pathway alone. This study evaluated the maximum tolerated dose/recommended phase II dose ... Full text Link to item Cite

Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML

Journal Article Journal of Geriatric Oncology · July 1, 2012 Objective: Older adults with acute myeloid leukemia (AML) tend to have worse complete remission (CR) rates and overall survival compared to their younger counterparts. At least one reason for this is increased expression of the multidrug resistance gene (M ... Full text Cite

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.

Journal Article Leuk Lymphoma · February 2012 Patients with chronic lymphocytic leukemia (CLL) with deletion or mutation of TP53 have exceedingly poor clinical outcomes. Cenersen, an oligonucleotide targeting TP53, has been shown to abrogate the activity of TP53 gain-of-function mutants and to increas ... Full text Link to item Cite

NCCN Clinical Practice Guidelines Occult primary.

Journal Article J Natl Compr Canc Netw · December 2011 Occult primary tumors, or cancers of unknown primary (CUPs), are defined as histologically proven metastatic malignant tumors whose primary site cannot be identified during pretreatment evaluation. They have a wide variety of clinical presentations and a p ... Full text Link to item Cite

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.

Journal Article Blood · October 13, 2011 B-cell chronic lymphocytic leukemia (CLL), an incurable leukemia, is characterized by defective apoptosis. We found that the SET oncoprotein, a potent inhibitor of the protein phosphatase 2A (PP2A) tumor suppressor, is overexpressed in primary CLL cells an ... Full text Link to item Cite

Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.

Journal Article Leukemia · September 2011 Monoclonal B-cell lymphocytosis (MBL) is a hematologic condition wherein small B-cell clones can be detected in the blood of asymptomatic individuals. Most MBL have an immunophenotype similar to chronic lymphocytic leukemia (CLL), and 'CLL-like' MBL is a p ... Full text Link to item Cite

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Journal Article J Clin Oncol · July 10, 2011 PURPOSE: Vaccination with hybridoma-derived autologous tumor immunoglobulin (Ig) idiotype (Id) conjugated to keyhole limpet hemocyanin (KLH) and administered with granulocyte-monocyte colony-stimulating factor (GM-CSF) induces follicular lymphoma (FL) -spe ... Full text Link to item Cite

Donor-transmitted malignancies in organ transplantation: assessment of clinical risk.

Journal Article Am J Transplant · June 2011 The continuing organ shortage requires evaluation of all potential donors, including those with malignant disease. In the United States, no organized approach to assessment of risk of donor tumor transmission exists, and organs from such donors are often d ... Full text Link to item Cite

Non-Hodgkin's lymphomas.

Journal Article J Natl Compr Canc Netw · May 2011 Full text Link to item Cite

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).

Journal Article Cancer Chemother Pharmacol · February 2011 PURPOSE: VEGF, mTOR, and EGFR inhibitors have demonstrated anti-tumor and anti-angiogenic effects alone and in combination with each other. This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus, and erlotinib combin ... Full text Link to item Cite

LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.

Journal Article Leukemia · September 2010 B-cell chronic lymphocytic leukemia (CLL) is characterized by slow accumulation of malignant cells, which are supported in the microenvironment by cell-cell interactions and soluble cytokines such as tumor necrosis factor (TNF). We evaluated the effect of ... Full text Link to item Cite

Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.

Journal Article Cancer Invest · July 2010 We present a study of the prevalence of genetic polymorphisms and expression of genes encoding the drug-resistance proteins glutathione S-transferases (GSTs) in order to gain insights into the pattern of failure evident in mantle cell lymphoma. We note a h ... Full text Link to item Cite

Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis.

Journal Article Leukemia · January 2010 Monoclonal B-cell lymphocytosis (MBL) is a preclinical hematologic syndrome characterized by small accumulations of CD5(+) B lymphocytes. Most MBL share phenotypic characteristics with chronic lymphocytic leukemia (CLL). Although some MBL progress to CLL, ... Full text Link to item Cite

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Journal Article Biol Blood Marrow Transplant · January 2010 The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous ste ... Full text Link to item Cite

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

Journal Article Anticancer Res · December 2009 AIM: To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination. PATIENTS AND METHODS: Thirty-nine evaluable patients with advanced solid tumors were treated with gemcit ... Link to item Cite

A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.

Journal Article Clin Cancer Res · November 15, 2009 PURPOSE: Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a variable clinical course. Several parameters have prognostic capabilities but are associated with altered response to therapy in only a small subset of patients. EXPERIME ... Full text Link to item Cite

Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.

Journal Article Leuk Lymphoma · October 2009 Recombinant interferon alpha-2b (IFN-alpha2) has direct and indirect antiproliferative effects in lymphoma, and may augment cytotoxicity when combined with chemotherapy. CALGB 8691 is a randomized study of daily oral cyclophosphamide (CPA) at 100 mg/m2 wit ... Full text Link to item Cite

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

Journal Article Leuk Lymphoma · October 2009 The humanized anti-CD52 monoclonal antibody alemtuzumab is an effective therapy for chronic lymphocytic leukemia (CLL). We examined the impact of alemtuzumab treatment after initial fludarabine treatment for feasibility and safety. Patients (N = 85) with p ... Full text Link to item Cite

Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.

Journal Article Cancer · July 1, 2009 BACKGROUND: Response and survival in 96 patients with secondary acute myeloid leukemia (sAML) who received aggressive induction chemotherapy was reviewed. METHODS: The median follow-up of survivors was 2.3 years. A total of 70 (73%) patients achieved a mor ... Full text Link to item Cite

Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.

Journal Article Leuk Lymphoma · May 2009 Non-cross resistant drugs given at high-dose intensity may maximise tumor cell kill leading to improved patient outcomes. We investigated the feasibility and efficacy of administering ifosfamide, carboplatin and etoposide +/- rituximab as sequential high-d ... Full text Link to item Cite

Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia.

Journal Article Leukemia · December 2008 Survival of chronic lymphocytic leukemia (CLL) cells requires sustained activation of the antiapoptotic PI-3-K/Akt pathway, and many therapies for CLL cause leukemia cell death by triggering apoptosis. Blood lipoprotein particles are either pro- or antiapo ... Full text Link to item Cite

Occult primary.

Journal Article J Natl Compr Canc Netw · November 2008 Full text Link to item Cite

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.

Journal Article Clin Cancer Res · October 1, 2008 PURPOSE: The primary aims of this phase I-II study were to determine the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary efficacy of the combination of docetaxel and the endothelin A receptor antagonist atrasentan as first ... Full text Link to item Cite

Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.

Journal Article Leuk Lymphoma · August 2008 Our aim was to estimate the duration of maximum tolerated dose (MTD) duration for gemcitabine given as a continuous infusion in combination with fludarabine and mitoxantrone and to evaluate potential pharmacokinetic (PK) interactions in 17 patients with re ... Full text Link to item Cite

CLL cell apoptosis induced by nitric oxide synthase inhibitors: correlation with lipid solubility and NOS1 dissociation constant.

Journal Article Leuk Res · July 2008 Nitric oxide synthase (NOS) inhibitors induce chronic lymphocytic leukemia (CLL) cell apoptosis and have potential as CLL therapeutics. We determined the half-maximal concentration (ED(50)) of 22 NOS inhibitors that induced CLL cell death in vitro. There w ... Full text Link to item Cite

Malignancy after solid organ transplantation: an overview.

Journal Article Oncologist · July 2008 With improving survival following solid organ transplantation, clinicians must be aware of post-transplant complications. One increasingly frequent complication is the development of malignancy after transplantation. The most common malignancies encountere ... Full text Link to item Cite

Non-Hodgkin's lymphomas.

Journal Article J Natl Compr Canc Netw · April 2008 Full text Link to item Cite

Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation.

Journal Article Am J Clin Pathol · December 2007 In the World Health Organization classification, cases with classical Burkitt morphologic features and a very high proliferation fraction but without the MYC translocation are not clearly designated as a separate entity and are usually categorized as diffu ... Full text Link to item Cite

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.

Journal Article Am J Hematol · December 2007 Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable region (IgV(H)) mutation status, cytogenetic abnorma ... Full text Link to item Cite

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

Journal Article Blood · June 15, 2007 Nelarabine (506U78) is a soluble pro-drug of 9-beta-D-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine. A ... Full text Link to item Cite

High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.

Journal Article Leuk Lymphoma · May 2007 Cyclophosphamide and doxorubicin, two important drugs in the treatment of lymphoma, exhibit a relationship between dose and fractional cell kill, and because of their toxicity profiles, they are candidates for significant dose escalation. We performed a ph ... Full text Link to item Cite

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

Journal Article J Clin Oncol · February 20, 2007 PURPOSE: Allogeneic transplantation is typically limited to younger patients having a matched donor. To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related do ... Full text Link to item Cite

Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification.

Journal Article Blood · February 15, 2007 Somatic mutations of immunoglobulin genes characterize mature memory B cells, and intraclonal B-cell diversification is typically associated with expansion of B-cell clones with greater affinity for antigen (antigen drive). Evidence for a role of antigen i ... Full text Link to item Cite

Salvage therapy in Hodgkin's lymphoma.

Journal Article Oncologist · February 2007 Hodgkin's disease is a rare malignancy that affects approximately 7,500 patients per year in the U.S., leading to an estimated 1,400 deaths. The relapse rate for this disease varies from around 5% for early-stage disease to 35% for patients with advanced d ... Full text Link to item Cite

Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.

Journal Article J Clin Oncol · February 1, 2006 PURPOSE: The treatment of early-stage Hodgkin's disease (HD) has evolved from radiotherapy alone (RT) to combined-modality therapy (CMT) because of concerns about late adverse effects from high-dose subtotal nodal irradiation (STNI). However, there is litt ... Full text Link to item Cite

Chronic lymphocytic leukemia cell CD38 expression and inducible nitric oxide synthase expression are associated with serum IL-4 levels.

Journal Article Leuk Res · January 2006 B cell chronic lymphocytic leukemia (CLL) CD38 expression is variable and may predict outcome. Inducible nitric oxide synthase (NOS2) expression regulates CLL cell apoptosis. IL-4 and IFN-gamma regulate B cell CD38 expression and NOS2 expression. We compar ... Full text Link to item Cite

Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.

Journal Article Ann Thorac Surg · August 2005 Doxorubicin-induced cardiomyopathy is not uncommon and may progress to end-stage heart failure. Treatment of this condition with heart transplantation, however, requires that the primary malignancy be deemed "cured." We present the case of a 55- year-old w ... Full text Link to item Cite

Occult primary cancer clinical practice guidelines.

Journal Article J Natl Compr Canc Netw · March 2005 Link to item Cite

Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.

Journal Article Cancer · November 1, 2004 BACKGROUND: Iodine-131 metaiodobenzylguanidine (131I-MIBG) is useful for imaging carcinoid tumors and recently has been applied to the palliative treatment of metastatic carcinoid in small studies. The authors now report their results on the therapeutic ut ... Full text Link to item Cite

Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.

Journal Article Clin Lymphoma · September 2004 A retrospective review was performed on the toxicity and response to one cycle of dose-intense cyclophosphamide/etoposide, followed by consolidation in patients with refractory or previously untreated, high-risk non-Hodgkin's lymphoma (NHL). Fifty-five pat ... Full text Link to item Cite

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.

Journal Article Blood · August 1, 2004 We report a phase 1 study of pharmacokinetics, dosimetry, toxicity, and response of (131)I anti-tenascin chimeric 81C6 for the treatment of lymphoma. Nine patients received a dosimetric dose of 370 MBq (10 mCi). Three patients received an administered acti ... Full text Link to item Cite

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.

Journal Article Cancer · June 1, 2004 BACKGROUND: Many patients with recurrent, intermediate or high-grade non-Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although high-dose taxanes have not bee ... Full text Link to item Cite

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.

Journal Article Clin Cancer Res · April 1, 2004 PURPOSE: Expansion and activation of natural killer (NK) cells with interleukin-2 (IL-2) may enhance antibody-dependent cellular cytotoxicity (ADCC), an important mechanism of rituximab activity. Two parallel Phase I studies evaluated combination therapy w ... Full text Link to item Cite

The impact of minimally invasive parathyroidectomy on the way endocrinologists treat primary hyperparathyroidism.

Conference Surgery · December 2003 BACKGROUND: Minimally-invasive parathyroidectomy (MIP) appears to be changing preoperative treatment and referral patterns for sporadic, nonfamilial, non-multiple endocrine neoplasia, primary hyperparathyroidism (PHPT). METHODS: The American Association of ... Full text Link to item Cite

Rituximab in lymphocyte predominance Hodgkin's disease: a case series.

Journal Article Clin Lymphoma · September 2003 Rituximab in combination with chlorambucil or radiation therapy may be an effective and less-toxic therapeutic alternative for patients with lymphocyte predominance Hodgkin's disease (LPHD). We treated 6 patients with LPHD with weekly rituximab at 375 mg/m ... Full text Link to item Cite

Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study.

Journal Article Cancer · March 15, 2003 BACKGROUND: African-American patients have been under-represented in oncology clinical trials. Better understanding barriers to African-American participation may help increase the accrual of African-American patients onto clinical trials. METHODS: Two hun ... Full text Link to item Cite

Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.

Journal Article Clin Cancer Res · February 2003 PURPOSE: The purpose of this study was to determine the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with fludarabine at 25 mg/m(2) daily for 5 days in the treatment of relapsed or refractory acute myelogenous leuk ... Link to item Cite

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.

Journal Article J Clin Oncol · July 1, 2002 PURPOSE: To estimate the maximum-tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with irinotecan at 40 mg/m(2) daily for 3 days in the treatment of relapsed or refractory acute leukemia or lymphoma. PATIENTS AND METHODS: Pati ... Full text Link to item Cite

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.

Journal Article Leuk Lymphoma · May 2002 Twenty-three adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) were treated for up to 12 weeks with the anti-CD52 monoclonal antibody alemtuzumab. Patients were a median of six years from diagnos ... Full text Link to item Cite

Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.

Journal Article J Clin Oncol · February 1, 2002 PURPOSE: To ascertain the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with mitoxantrone at 12 mg/m(2) daily for 3 days in the treatment of acute leukemia. PATIENTS AND METHODS: Thirty-four patients were enrolled. ... Full text Link to item Cite

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.

Journal Article Cancer · July 15, 2001 BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies ev ... Full text Link to item Cite

Phase i trial of continuously infused gemcitabine with cpt-11 for refractory hematologic malignancies

Journal Article Blood · December 1, 2000 In vitro modeling suggests additive efficacy of the nucleoside analogue gemcitabine with the topoisomerease inhibitor CPT-11. We are performing a phase I trial for patients with refractory leukemia or lymphoma using 1 cycle of variable durations of infusio ... Cite

Fine-needle aspiration with flow cytometric immunophenotyping for primary diagnosis of intra-abdominal lymphomas.

Journal Article Diagn Cytopathol · August 1999 Cytomorphology in conjunction with immunophenotypic characterization is becoming increasingly used for the primary diagnosis of non-Hodgkin's lymphomas (NHL). This combination is especially advantageous for the diagnosis of intra-abdominal and intrathoraci ... Full text Link to item Cite

Renal lymphoma in an azotemic patient--usefulness of magnetic resonance imaging.

Journal Article Scand J Urol Nephrol · April 1999 An azotemic patient benefited from diagnostic magnetic resonance imaging (MRI) in the evaluation of his renal mass. This led to suspicion of lymphoma, and provided guidance for percutaneous biopsy. Chemotherapy was then initiated, and an unnecessary nephre ... Full text Link to item Cite

Malignant melanoma presenting as a mediastinal mass.

Journal Article Ann Thorac Surg · March 1999 A case of malignant melanoma presenting as a mediastinal mass without an extrathoracic primary is reported. Microscopically the tumor appeared consistent with malignant melanoma, with the presence of focal melanin pigment in large epithelioid cells. Fontan ... Full text Link to item Cite

Acute leukemia following treatment of malignant glioma.

Journal Article J Neurooncol · October 1998 We report two patients with acute myeloid leukemia (AML) following therapy for malignant glioma; one was a young women treated heavily with alkylating agents for glioblastoma and the other a young man treated with high doses of procarbazine, lomustine, and ... Full text Link to item Cite

Iodine-131-metaiodobenzylguanidine uptake in metastatic carcinoid tumor to the orbit.

Journal Article J Nucl Med · April 1998 Metastatic tumor is one of several etiologies of space-occupying masses in the orbit that accounts for 1%-13% of all orbital masses (1). In the adult patient population, breast cancer is the most common tumor to metastasize to the orbit followed by metasta ... Link to item Cite

Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.

Journal Article J Clin Oncol · March 1998 PURPOSE: To determine the incidence of myelodysplasia (MDS) and/or acute leukemia (AL) in breast cancer patients after high-dose chemotherapy (HDC) with a single conditioning regimen and autologous bone marrow transplant (ABMT), and analyze the cytogenetic ... Full text Link to item Cite

Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells.

Journal Article Leuk Res · August 1995 Freshly isolated acute non-lymphocytic leukemia (ANLL) cells were treated with the nitric oxide (NO)-liberating compounds sodium nitroprusside or S-nitrosoacetyl penicillamine and analyzed for viability, growth, and differentiation at 3-5 days. NO decrease ... Full text Link to item Cite

Primary central nervous system lymphoma with systemic metastasis: case report and review.

Journal Article J Neurooncol · 1995 Primary central nervous system lymphoma (PCNSL) almost always remains confined to the nervous system. We report a patient with well documented PCNSL who responded to treatment, but subsequently developed pathologically confirmed systemic metastases without ... Full text Link to item Cite

Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy.

Journal Article Neurology · September 1994 The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients. Primary lesions were reduced by 80% or more on contrast ... Full text Link to item Cite

A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease.

Journal Article Cancer · July 1, 1994 BACKGROUND: Advanced stage Hodgkin's disease (HD) usually is treated with combination chemotherapy with or without supplemental irradiation. The risk of significant acute and long term toxicity when the chemotherapy regimen contains alkylating agents has p ... Full text Link to item Cite

The radiographic diagnosis and treatment of paraneoplastic central nervous system disease.

Journal Article Cancer · January 1, 1994 Paraneoplastic nervous system syndromes are being identified with increasing frequency because of greater physician awareness and the availability of serodiagnostic tests for some syndromes. Frequently, paraneoplastic syndromes develop in the setting of an ... Full text Link to item Cite

Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.

Journal Article Thromb Haemost · March 2, 1992 Progressive thrombocytopenia may develop in as many as 5% of patients receiving heparin anticoagulation. In these patients, the risk of thromboembolic complications as well as continued thrombocytopenia necessitates discontinuation of heparin and initiatio ... Link to item Cite

Fluconazole and Candida krusei fungemia.

Journal Article N Engl J Med · October 31, 1991 Link to item Cite

The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.

Journal Article Cancer · October 15, 1991 An ocular toxic reaction presenting as conjunctivitis or keratitis develops in a significant number of patients who are treated with high-dose cytosine arabinoside (ara-C). Although eye drops containing glucocorticoid reportedly decrease the incidence, the ... Full text Link to item Cite

Improved survival in advanced Hodgkin's disease with the use of combined modality therapy.

Journal Article Int J Radiat Oncol Biol Phys · September 1990 To compare the effectiveness of combined modality therapy and chemotherapy alone for the treatment of advanced Hodgkin's disease (Stages IIB-IV), records of 154 patients who achieved a complete or partial response to induction combination chemotherapy were ... Full text Link to item Cite

The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.

Journal Article Cancer · August 1, 1990 Forty-five patients have completed treatment with AFM, an intensive induction chemotherapy regimen composed of Adriamycin (doxorubicin, Adria Laboratories, Columbus, Ohio), 5-fluorouracil, and methotrexate with folinic acid rescue. This regimen was designe ... Full text Link to item Cite

Phase I studies of recombinant interferon-gamma.

Journal Article J Biol Response Mod · April 1990 A phase I study of the effects of intravenous administration of interferon-gamma on 31 patients was performed. The effects of dose, schedule, and chronic administration were studied. In the first phase of the study, a dose range of 0.01-500 MU/m2 (0.0002-2 ... Link to item Cite

Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia.

Journal Article Am J Clin Pathol · March 1989 The authors performed membrane antigen phenotyping on 75 patients with acute nonlymphocytic leukemia with a panel of myeloid-associated monoclonal antibodies. The 34 patients (45%) with CD34-positive leukemia were not significantly different from the 41 wi ... Full text Link to item Cite

High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.

Journal Article Cancer Chemother Pharmacol · 1989 A total of 23 patients were treated at five dose escalations with high-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 18 ... Full text Link to item Cite

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.

Journal Article J Clin Oncol · September 1988 To evaluate the effect of high-dose chemotherapy in the treatment of metastatic breast cancer, we performed a phase II trial of a single treatment with high-dose cyclophosphamide (5,625 mg/m2), cisplatin (165 mg/m2), and carmustine (600 mg/m2), or melphala ... Full text Link to item Cite

Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support.

Journal Article Transplantation · July 1988 Altered immunologic reconstitution is observed in patients treated with high-dose chemotherapy consisting of cyclophosphamide, cisplatin, and carmustine, melphalan, or etoposide with autologous bone marrow support, and it is similar to that seen in patient ... Full text Link to item Cite

Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia.

Journal Article Leuk Res · 1988 On the basis of in-vitro studies indicating that low concentrations of cytosine arabinoside exert preferential inhibition of granulocyte-macrophage colony-forming cells from patients with chronic granulocytic leukemia vs normal subjects, we treated two out ... Full text Link to item Cite

Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors.

Journal Article Cancer Res · December 1, 1987 A Phase I-II clinical trial of high dose single agent busulfan (16-20 mg/kg) administered over a 4-day period was undertaken. Pharmacokinetic measurements reveal that steady state total plasma busulfan levels between 2 and 10 microM were achieved by the se ... Link to item Cite

Effects of gamma-interferon on the endocrine system: results from a phase I study.

Journal Article Cancer Res · December 1, 1987 Interferon causes profound biological changes when given to patients with cancer and many of these could not be predicted from in vitro or animal model systems. We documented significant changes in hormonal levels for a group of 18 patients who were partic ... Link to item Cite

Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults.

Journal Article Am J Med · October 23, 1987 The standard schedule for treating immune thrombocytopenia purpura in adults with intravenous immunoglobulin G infusion (IVIG), 400 mg/kg per day for five days, was compared with a shorter schedule using 1,000 mg/kg per day for two days. Both schedules wer ... Full text Link to item Cite

Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial.

Journal Article Cancer Treat Rep · October 1986 In a randomized study 115 postmenopausal women with advanced breast cancer who were estrogen receptor-unknown or -positive were treated initially with tamoxifen or diethylstilbestrol (DES). Their pretreatment characteristics showed no significant differenc ... Link to item Cite

Gastrointestinal involvement and multiple lymphomatous polyposis in mantle-zone lymphoma.

Journal Article J Clin Oncol · June 1986 The clinical, histologic, and immunologic features of three cases of lymphoma presenting with gastrointestinal symptoms and involving the gastrointestinal tract were studied. Two of the cases had involvement of long segments of the bowel with polypoid lesi ... Full text Link to item Cite

Pneumonia in bone marrow transplant patients.

Journal Article AJR Am J Roentgenol · October 1984 The radiographic, pathologic, and clinical features of 22 episodes of pneumonia in 18 bone marrow transplant recipients were analyzed retrospectively. These pneumonias could be divided into three diagnostic categories: (1) a transient form of nonspecific i ... Full text Link to item Cite

Oral candidiasis in cancer patients.

Journal Article South Med J · March 1984 Oral candidiasis in cancer patients is an infection for which inconsistent diagnostic and therapeutic strategies currently prevail. Recent studies have shown its potential importance in the development of systemic candidiasis. A clinical and cytologic stud ... Full text Link to item Cite

Bone-marrow transplantation in a patient with sickle-cell anemia

Journal Article New England Journal of Medicine · 1984 This report describes the conversion of sickle-cell anemia to sickle-cell trait by marrow transplantation (done for treatment of leukemia) in a child with both sickle-cell anemia and acute myeloblastic leukemia. It raises the possibility of using marrow tr ... Cite

Oral manifestations of the chronic graft-v-host reaction.

Journal Article JAMA · January 28, 1983 The graft-v-host reaction (GVHR), a major complication of bone marrow transplantation, is a complex immunologic phenomenon with a diverse and often confounding presentation. After reviewing major systemic manifestations, this report details the clinical an ... Link to item Cite

Drug-induced interstitial lung diseases.

Journal Article Clin Chest Med · September 1982 Any discussion of drug-induced interstitial lung disease is fraught with the problem of having a syndrome in which information is composed predominantly of case reports. When the information is taken as a whole, however, the picture becomes clearer: (1) So ... Link to item Cite

Hereditary thrombotic thrombocytopenic purpura: microangiopathic hemolytic anemia, thrombocytopenia, and renal insufficiency occurring in consecutive generations.

Journal Article Nephron · 1982 Microangiopathic hemolytic anemia, thrombocytopenia, and renal insufficiency occurred in a mother an daughter when each was in her third decade. The mother had prominent neurological findings, fever, and expired from renal insufficiency. Her daughter's onl ... Full text Link to item Cite

Kinetics of elimination of antithrombin III concentrate in heparinized patients.

Journal Article Br J Haematol · August 1981 The rate of elimination of injected antithrombin III (AT III) concentrate was investigated by measuring plasma AT III levels in two control subjects and four patients treated with continuous intravenous infusion of heparin. No significant differences were ... Full text Link to item Cite

Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein.

Journal Article Cancer · May 15, 1980 This study reports the use of radiolabeled antibodies to alpha-fetoprotein for the detection and localization of hepatocellular and germ cell carcinomas. Twelve patients with histories of histologically-confirmed neoplasia received a total dose between 1.0 ... Full text Link to item Cite

The lipids of the erythrocyte in paroxysmal nocturnal hemoglobinuria.

Journal Article Am J Hematol · 1978 Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder characterized by the production of abnormal erythrocytes (PNH-E). The PNH-E undergoes early intravascular destruction which appears to be related to an intrinsic membrane defect that results in extrem ... Full text Link to item Cite

Heparin-induced decrease in circulating antithrombin-III.

Journal Article Lancet · September 17, 1977 Plasma-antithrombin-III (AT-III) concentrations were measured throughout therapy in 24 patients receiving continuous intravenous heparin infusion and in 2 patients treated with repeated intravenous heparin injections. In all patients, including 1 with cong ... Full text Link to item Cite

RBC transfusions in paroxysmal nocturnal hemoglobinuria.

Journal Article Arch Intern Med · April 1977 Frozen-thawed, deglycerolized RBCs can be substituted for saline-washed RBCs for transfusion of patients with paroxysmal nocturnal hemoglobinuria (PNH). The effect of transfusion is to decrease bone marrow production of RBCS, which results in a decreased p ... Link to item Cite

Effect of heparin on circulating antithrombin III level

Journal Article Thrombosis and Haemostasis · January 1, 1977 Full text Cite

Effect of heparin therapy on antithrombin III

Journal Article Clinical Research · January 1, 1977 Cite

Procoagulant and platelet aggregating properties of antilymphocyte sera.

Journal Article J Lab Clin Med · May 1976 Ten anti-human lymphocyte sera in clinical use at six transplant centers and five anti-nonhuman lymphocyte sera were studied for their procoagulant and platelet-aggregating properties. This investigation was initiated following the observation of a clinica ... Link to item Cite

The abnormal surface characteristics of the red blood cell membrane in congenital dyserythropoietic anaemia type II (HEMPAS).

Journal Article Br J Haematol · August 1975 The red blood cell membranes of patients with congenital dyserythropoietic anaemia Type II (CDA-II) were found to be abnormal. They had altered antigenic characteristics, decreased electrophoretic mobility, decreased sialic acid content, and abnormal filtr ... Full text Link to item Cite

Vitamin A in liposomes. Inhibition of complement binding and alteration of membrane structure.

Journal Article Biochim Biophys Acta · June 25, 1975 Incorporation of vitamin A aldehyde (retinal) into liposomes had an inhibitory effect on the amount of human complement protein bound in the presence of specific antiserum. The total membrane-bound protein was directly measured on liposomes which were wash ... Full text Link to item Cite

Alteration of human erythrocyte membrane properties by complement fixation.

Journal Article J Clin Invest · April 1975 Erythrocyte survival studies of complement-coated radiolabeled erythrocytes have shown rapid removal of these cells from the peripheral blood with a return of these cells into the circulation within a few hours. We studied complement-coated human erythrocy ... Full text Link to item Cite

Detection of platelet isoantibodies by (3H)serotonin platelet release and its clinical application to the problem of platelet matching.

Journal Article J Clin Invest · January 1975 The detection of platelet isoantibodies by the release of (3H)serotonin from platelets has been evaluated. The conditions for optimal release of (3H)serotonin with platelet isoantibodies using a microtechnique have been defined. A group of cardiac surgery ... Full text Link to item Cite

Abnormal lipid composition of the red cell membrane in congenital dyserythropoietic anemia type II (HEMPAS).

Journal Article J Lab Clin Med · January 1975 The lipids derived from the erythrocytes of two siblings with clinical congenital dyserythropietic anemia Type II (CDA-II) and one sibling without clinical evidence of CDA-II underwent a detailed analysis. The total phospholipids, total cholesterol, and ch ... Link to item Cite

Accumulations of N acetyl glucosamine containing glycolipids in erythrocyte stroma of patients with congenial dyserythropoietic anemia type II (HEMPAS)

Journal Article Clinical Research · January 1, 1975 Congenital Dyserythropoietic Anemia Type II (HEMPAS) is characterized by ineffective erythropoiesis, erythroblastic multinuclearity, increased erythrocyte reactivity with anti i serum, and shortened survival time of the erythrocyte in the peripheral circul ... Cite

Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome.

Journal Article J Clin Invest · February 1973 The amount of the third component of complement (C3) bound to red cells of patients with the cold agglutinin syndrome was determined by a quantitative assay, measuring the fixation of the first component of complement by anti-C3. Abrupt reduction in the se ... Full text Link to item Cite

Type II congenital dyserythropoietic anemia.

Journal Article Ann Intern Med · September 1972 Full text Link to item Cite

ELECTROPHORETIC SEPARATION OF MULTIPLE FORMS OF PARTICLE ASSOCIATED

Journal Article Annals of the New York Academy of Sciences · 1964 Cite